pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,760 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1156Endpoints875BioPharma Dive339BioSpace298Fierce Biotech277onclive165raps104globenewswire health73
therapy area
allOncology7399Rare Disease1831Cardiology1673Immunology1467Hematology1302Vaccines1181Pulmonology
  • Michigan lawmakers introduce bipartisan bill to curb China-U.S. biotech partnerships
    A bipartisan group of Michigan legislators has unveiled a new bill aimed at limiting cross-border transactions between Chinese and American biotechnology firms. The proposal, introduced by Rep. Jo…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Abivax’s ulcerative colitis Phase 3 trial shows promising efficacy but cancer cases raise safety concerns
    Abivax announced that its Phase 3 maintenance trial in ulcerative colitis produced results it called “landmark,” showing the drug’s ability to keep patients in remission. The company emphasized th…
    Endpoints · 3mo agoNegative readoutNegative↗ source
← prev
page 51 of 71
next →
fda recalls67
fda medwatch60
fda press38
1088
Psychiatry & CNS860
Ophthalmology492
Pain470
Endocrinology & Metabolism466
Infectious Disease439
  • US-made packaging equipment offers faster lead times and regulatory alignment for pharma manufacturers
    As pharma firms upgrade their packaging lines, the source of the equipment is becoming a strategic factor rather than a simple purchasing decision. Domestic production shortens lead times and redu…
    BioPharma Dive · 3mo agoPositive↗ source
  • Praxis Precision Medicines reports late-stage failure of seizure drug and pauses second trial
    Praxis Precision Medicines had enjoyed a period of momentum, reporting two notable clinical successes in the past eight months. The company’s pipeline had been viewed positively by investors and an…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Eli Lilly gives hospitals five days to meet new 340B claims data policy or lose discounts
    Eli Lilly has told a group of hospitals they must adhere to a new claims data policy within five days or their participation in the 340B drug discount program will be terminated. The policy requir…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • ASCO 2026 hints at future role for VEGF-targeted cancer drugs as complement to immunotherapy
    At the recent ASCO meeting, experts discussed the outlook for VEGF-targeted therapies in oncology. Earlier hopes that this new class could match the blockbuster success of pembrolizumab (Keytruda)…
    Endpoints · 3mo agoNeutral↗ source
  • Fulcrum Therapeutics abandons its only sickle cell drug after FDA cites concerns linked to withdrawn cancer therapy
    Fulcrum Therapeutics announced it is ending development of its sole clinical‑stage sickle cell medicine. The move follows feedback from the U.S. Food and Drug Administration that referenced a rece…
    Endpoints · 3mo agoRegulatoryNegative↗ source
  • Obesity care startup Ilant Health secures $15M Series A funding
    Ilant Health, a startup focused on obesity care, announced a $15 million Series A financing round. The capital will be used to broaden its personalized treatment platform, which leverages virtual…
    Endpoints · 3mo agoDealPositive↗ source
  • Servier to acquire Edgewise's experimental muscular dystrophy drug in $2.7B deal
    Servier, a French pharmaceutical company, announced it will acquire the muscular dystrophy business of Colorado biotech Edgewise Therapeutics. The deal centers on sevasemten, an experimental oral…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Eli Lilly's $7B acquisition of Kelonia highlighted by full-cohort response in in-vivo CAR-T trial for multiple myeloma
    At ASCO 2026, Kelonia Therapeutics presented data on its in-vivo CAR-T platform for multiple myeloma. The report covered 18 patients treated with the therapy, all of whom showed encouraging outcom…
    Endpoints · 3mo agoDealPositive↗ source
  • Servier acquires Edgewise's muscular dystrophy assets for $1.55 billion
    Servier announced it will purchase the muscular dystrophy business from Edgewise Therapeutics. The deal involves an upfront payment of $1.55 billion, giving the French company rights to Edgewise's…
    Endpoints · 3mo agoDealPositive↗ source
  • AstraZeneca reports promising triplet therapy results in liver cancer subgroup
    AstraZeneca presented new data at ASCO 2026 showing that a regimen combining a targeted agent with two immunotherapies produced clinical benefit in a subset of liver cancer patients. The study eva…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Priority review voucher prices have doubled over three years, likely to remain high
    Recent reporting highlights that the price of FDA priority review vouchers has roughly doubled from three years ago. The vouchers provide a shortcut that can shave about four months off the agency…
    Endpoints · 3mo agoRegulatoryNeutral↗ source
  • CRISPR-based epigenetic editing shows promise in silencing hepatitis B genes
    A new CRISPR-based technique targets the epigenome to turn off genes that drive chronic hepatitis B infection, doing so without changing the underlying DNA sequence. Tune Therapeutics reported ear…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Shionogi receives FDA nod for first oral COVID-19 post-exposure prevention pill
    Shionogi announced that the U.S. Food and Drug Administration has granted approval for its oral antiviral designed to prevent COVID-19 after exposure. The product is indicated for adults and child…
    Endpoints · 3mo agoApprovalPositive↗ source
  • Agios pays $25 million for global rights to Oscotec’s SYK inhibitor cevidoplenib
    Agios Therapeutics announced it has secured an exclusive worldwide license for Oscotec’s experimental SYK inhibitor, cevidoplenib. Under the agreement, Agios will pay $25 million up front to Oscot…
    Endpoints · 3mo agoDealNeutral↗ source
  • Avenzo Therapeutics to go public via reverse merger with Rallybio after Candid partnership ends
    On June 1, 2026, Avenzo Therapeutics announced that it will become a publicly traded company through a reverse merger with Rallybio, securing a Nasdaq listing after its previous partner, Candid, en…
    Endpoints · 3mo agoDealPositive↗ source
  • Turn Therapeutics reports faster symptom relief in Phase 2 eczema trial
    Turn Therapeutics, a California biotech, disclosed interim results from its Phase 2 study of a topical treatment for atopic dermatitis. The analysis of 50 patients indicated that skin symptoms imp…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • J&J’s Erleada reduces metastasis or death risk by 20% in early‑stage prostate cancer study
    Johnson & Johnson presented data on its hormone therapy drug Erleada at the ASCO 2026 meeting. The study focused on men with early‑stage prostate cancer who received the drug around the time of sur…
    Endpoints · 3mo agoPositive readoutPositive↗ source
  • Orphan drug sales projected to exceed 21% of prescription market by 2032, driven by strong pipeline and policy support
    Orphan drug developers continue to see robust sales growth even as the broader pharmaceutical industry faces pricing and policy turbulence. The latest Evaluate Orphan Drugs Report highlights that s…
    BioPharma Dive · 3mo agoPositive↗ source
  • Oculis’ investigational eye drop OCS-01 fails Phase 3 trials for diabetic macular edema, shares tumble
    Oculis announced that its experimental eye drop OCS-01 did not meet primary endpoints in two Phase 3 studies aimed at treating diabetic macular edema. The trials were intended to evaluate the drug…
    Endpoints · 3mo agoNegative readoutNegative↗ source
  • Eli Lilly licenses Hanmi's GLP-2 asset for $75 million upfront
    Eli Lilly has signed a licensing agreement with South Korean biotech Hanmi to acquire rights to a GLP-2 drug candidate, paying an upfront cash payment of $75 million. The deal marks Lilly's entry…
    Endpoints · 3mo agoDealNeutral↗ source
  • RallyBio pursues second reverse merger, this time with cancer drug developer Avenzo Therapeutics
    RallyBio announced on Monday that it will merge with cancer-focused Avenzo Therapeutics in a reverse‑merger transaction. The combined entity will operate under the Avenzo Therapeutics name. The de…
    BioPharma Dive · 3mo agoDealNeutral↗ source
  • #ASCO26: Lilly's plenaries; Incyte's frontline data in lymphoma
    Two plenaries related to Lilly: Researchers detailed findings from an investigator-sponsored trial using Lilly’s CDK4/6 inhibitor Verzenio in a rare cancer called dedifferentiated liposarcoma, show…
    Endpoints · 3mo agoNeutral↗ source
  • Revolution Medicines' daraxonrasib nearly doubles survival in pancreatic cancer trial
    Data presented at the American Society of Clinical Oncology meeting showed that Revolution Medicines' experimental drug daraxonrasib significantly extended survival for patients with metastatic pan…
    BioPharma Dive · 3mo agoPositive readoutPositive↗ source